Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Department of Cardiology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
BMJ Open. 2021 Feb 22;11(2):e045482. doi: 10.1136/bmjopen-2020-045482.
Recent reports suggest a high prevalence of hypertension and diabetes in COVID-19 patients, but the role of cardiovascular disease (CVD) risk factors in the clinical course of COVID-19 is unknown. We evaluated the time-to-event relationship between hypertension, dyslipidaemia, diabetes and COVID-19 outcomes.
We analysed data from the prospective Dutch CovidPredict cohort, an ongoing prospective study of patients admitted for COVID-19 infection.
Patients from eight participating hospitals, including two university hospitals from the CovidPredict cohort were included.
Admitted, adult patients with a positive COVID-19 PCR or high suspicion based on CT-imaging of the thorax. Patients were followed for major outcomes during the hospitalisation. CVD risk factors were established via home medication lists and divided in antihypertensives, lipid-lowering therapy and antidiabetics.
The primary outcome was mortality during the first 21 days following admission, secondary outcomes consisted of intensive care unit (ICU) admission and ICU mortality. Kaplan-Meier and Cox regression analyses were used to determine the association with CVD risk factors.
We included 1604 patients with a mean age of 66±15 of whom 60.5% were men. Antihypertensives, lipid-lowering therapy and antidiabetics were used by 45%, 34.7% and 22.1% of patients. After 21-days of follow-up; 19.2% of the patients had died or were discharged for palliative care. Cox regression analysis after adjustment for age and sex showed that the presence of ≥2 risk factors was associated with increased mortality risk (HR 1.52, 95% CI 1.15 to 2.02), but not with ICU admission. Moreover, the use of ≥2 antidiabetics and ≥2 antihypertensives was associated with mortality independent of age and sex with HRs of, respectively, 2.09 (95% CI 1.55 to 2.80) and 1.46 (95% CI 1.11 to 1.91).
The accumulation of hypertension, dyslipidaemia and diabetes leads to a stepwise increased risk for short-term mortality in hospitalised COVID-19 patients independent of age and sex. Further studies investigating how these risk factors disproportionately affect COVID-19 patients are warranted.
最近的报告表明,COVID-19 患者中高血压和糖尿病的患病率很高,但心血管疾病(CVD)危险因素在 COVID-19 临床病程中的作用尚不清楚。我们评估了高血压、血脂异常、糖尿病与 COVID-19 结局之间的时事件关系。
我们分析了正在进行的前瞻性荷兰 CovidPredict 队列中前瞻性研究的患者数据,该研究是对 COVID-19 感染住院患者的研究。
来自 8 家参与医院的患者,包括 CovidPredict 队列中的 2 家大学医院。
住院的、患有阳性 COVID-19 PCR 或基于胸部 CT 成像高度怀疑 COVID-19 感染的成年患者。患者在住院期间接受主要结局的随访。CVD 危险因素通过家庭用药清单确定,并分为抗高血压药、降脂治疗和抗糖尿病药。
主要结局是入院后 21 天内的死亡率,次要结局包括重症监护病房(ICU)入院和 ICU 死亡率。使用 Kaplan-Meier 和 Cox 回归分析来确定与 CVD 危险因素的关联。
我们纳入了 1604 名平均年龄为 66±15 岁的患者,其中 60.5%为男性。45%、34.7%和 22.1%的患者使用了抗高血压药、降脂治疗和抗糖尿病药。在 21 天的随访后,19.2%的患者死亡或出院接受姑息治疗。调整年龄和性别后 Cox 回归分析显示,存在≥2 个危险因素与死亡率增加相关(HR 1.52,95%CI 1.15 至 2.02),但与 ICU 入院无关。此外,使用≥2 种抗糖尿病药和≥2 种抗高血压药与死亡率相关,独立于年龄和性别,HR 分别为 2.09(95%CI 1.55 至 2.80)和 1.46(95%CI 1.11 至 1.91)。
高血压、血脂异常和糖尿病的积累导致住院 COVID-19 患者短期死亡率呈阶梯式增加,与年龄和性别无关。需要进一步研究这些危险因素如何不成比例地影响 COVID-19 患者。